| 共同演者 |
Naito Yuji（Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Japan）, Takagi Tomohisa（Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Japan）, Fukuda Wataru（Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Japan）, Harusato Akihito（Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Japan）, Yoshida Naohisa（Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Japan）, Katada Kazuhiro（Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Japan）, Kamada Kazuhiro（Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Japan）, Ishikawa Takeshi（Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Japan）, Handa Osamu（Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Japan）, Yasuda Hiroaki（Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Japan）, Sakagami Jun-ichi（Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Japan）, Konishi Hideyuki（Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Japan）, Yagi Nobuaki（Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Japan） |
| 抄録 |
Background and Aims：In the UC patients, it has been reported that recurrent inflammation with ulceration confers an increased risk of colitis-associated cancer. In the present study, we investigated the clinical course and background of the patients with colitis-associated cancer related to UC in our hospital. Methods：All patients were attending the gastroenterology outpatient clinic at the Hospital of the Kyoto Prefectural University of Medicine. 199 patients with UC were enrolled and investigated for the development of colitis-associated colorectal cancer. Results：A total of 8 patients were developed colitis-associated cancer during the median follow-up time 19.4 years. In contrast, the follow-up time of patients without cancer was 10.6 years. All the patients developed colorectal cancer were diagnosed as pan-colitis type. The age of onset with UC（cancer/non cancer：33.6/34.8 years）and distinction of sex（cancer F/M：4/4, non cancer F/M：92/99）and the use of medication including 5-ASA, steroid, and immunomodulators showed no difference between the patients with and without colitis-associated cancer. Conclution：In our study, cumulative incidence rates of colitis-associated cancer over 10 and 20 years were 2.0% and 4.0% in all patients of UC. For pan-colitis type of UC, incidence rate over 10 and 20 years were 4.9% and 9.8%. The special attention of surveillance should be paid for UC patients with pan-colitis type and over 10 years of follow-up time. |
